Scholar Rock's drug helps preserve lean mass in mid-stage trial

Scholar Rock's experimental drug, apitegromab, demonstrated positive results in a mid-stage trial when used with Eli Lilly's Zepbound, preserving an additional 1.9 kilograms of lean mass compared to Zepbound alone, and leading to greater fat mass loss; the announcement spurred a 16% jump in Scholar Rock's premarket trading, mirroring Regeneron's recent positive data combining its drug with Novo Nordisk's Wegovy.

Analysis

Scholar Rock (SRRK.O) reported positive mid-stage trial results for its experimental drug, apitegromab, when used in combination with Eli Lilly's (LLY.N) weight-loss treatment Zepbound, demonstrating that patients preserved an additional 1.9 kilograms of lean mass and experienced greater fat mass loss compared to Zepbound alone. This news, which spurred a 16% premarket increase in Scholar Rock's shares, is significant as it addresses the critical issue of muscle loss associated with GLP-1 agonist-induced weight reduction, potentially enhancing the therapeutic profile of such treatments. The findings position apitegromab as a promising adjunctive therapy within the rapidly expanding obesity drug market, a trend mirrored by Regeneron's recent similar positive data with its own experimental drug in conjunction with Novo Nordisk's Wegovy. For Scholar Rock, these results mark a substantial de-risking event for apitegromab's development in this indication and underscore a growing industry focus on optimizing outcomes beyond mere weight reduction.

Key Decisions for Investors

• Investors in Scholar Rock (SRRK) should consider the positive mid-stage trial data for apitegromab a significant de-risking event, yet remain cognizant of future clinical development stages and regulatory approval processes.
• The development of muscle-preserving adjunct therapies, such as apitegromab, could enhance the overall market appeal and patient adherence for leading GLP-1 drugs from companies like Eli Lilly (LLY) and Novo Nordisk (NVO), potentially leading to broader adoption and longer treatment durations.